Multikinase Inhibitor Treatment in Thyroid Cancer
Volume: 21, Issue: 1, Pages: 10 - 10
Published: Dec 18, 2019
Abstract
Thyroid cancer is the most common endocrine malignancy. Most thyroid cancer types respond well to conventional treatment consisting of surgery and radioactive iodine (RAI) therapy. Unfortunately, some thyroid cancer types are resistant to surgical and RAI therapy. Multikinase inhibitors (MKIs) can be used in the treatment of advanced refractory thyroid cancers. The objective of this review is to give an update on MKI treatment (lenvatinib,...
Paper Details
Title
Multikinase Inhibitor Treatment in Thyroid Cancer
Published Date
Dec 18, 2019
Volume
21
Issue
1
Pages
10 - 10
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History